We compared pathological prognostic stage (PPS) with anatomic stage (AS) groups according to the updated version of breast cancer staging of the American Joint Committee on Cancer (AJCC) 8 th Edition.
Background
At the end of 2016, the AJCC Cancer Staging Manual 8 th Edition was published [1] . T, N, M, ER, PR, HER2, and tumor grade biomarkers were used for breast cancer staging in the prognostic stage group. Oncotype DX is required for patients who are classified as T1-T2, N0, M0, grade 1-3, HER2 negative, and ER positive. Patients with Oncotype DX recurrence score <11 are classified as pathologic prognostic stage IA. The updated breast chapter was released in December 2017. The pathologic prognostic staging group was established with patients who underwent surgery for primary treatment, without any neoadjuvant treatment [2] . There was no change in the anatomic stage group. In the present study, we compared the pathologic prognostic stage and anatomic stage of patients with breast cancer, according to the AJCC 8 th Edition.
Material and Methods
We retrospectively evaluated 353 patients (stages I-III) treated with surgery as a primary treatment for breast cancer at the Institute of Oncology in Istanbul University between January 2004 and September 2006. Tumor size, lymph node involvement, distant metastasis, ER status, PR status, HER2 status, and tumor grade information were recorded. The histological grade of tumors was evaluated according to the ElstonEllis modification of the Scarff-Bloom-Richardson grading system [3] . ER status was determined by immunohistochemistry and it was recorded as the rate of positively stained cells. The cut-off value was 1% for patients who received treatment [4] . PR status was also determined by immunohistochemistry, and if 1% or more of the cells were stained, it was considered as PR-positive. 3+ in immunohistochemistry or gene amplification demonstrated through fluorescence in situ hybridization were accepted as HER2-positive [5] . The clinicopathologic information of patients is presented in Table 1 . The anatomic staging and pathologic prognostic staging according to breast cancer of the updated version of the AJCC 8 th Edition were performed on the patients. Stage changes were investigated. We determined which patients were ER-positive, HER2-negative, T1-T2, N0, and who were eligible for an Oncotype DX multigene test, which was recommended to be used in pathological prognostic staging in the AJCC 8 th Edition. Our patients did not have Oncotype DX multi-gene analysis. If the test was not performed, the appropriate stage was recorded, according to the new staging. Because biological markers are very important in the new staging system, and because they affect the survival rate, 64 patients who had not received trastuzumab in adjuvant treatment were excluded from the survival analysis, so 289 patients remained for the analysis. This study was performed in compliance with the Declaration of Helsinki.
Disease-specific survival (DSS) was calculated from the date of the operation to the date of death or the date of last control. If patients died for any other reason except breast cancer, they were censored on the date of death. Disease-free survival (DFS) was calculated from the operation date to the recurrence date of disease. SPSS software was used for statistical analysis (Version 20, IBM Corp., Armonk, NY, USA). We calculated 5-year and 10-year DFS and DSS according to both staging systems by using the Kaplan-Meier test. The Kappa test was performed by analyzing the degree of stage change, the rates of upstaging and downstaging. Each anatomic stage was re-classified according to the pathologic prognostic stage and the changed stages were compared with the chi-square test in terms of 10-year DFS and 10-year DSS. A p value <0.05 was considered statistically significant.
Results
The median follow-up was 114 months (range, 6-178 months), the median age was 48 years (range, 24-79 years). The patient characteristics are presented in Table 1 Tables 2, 3 ). 64 (18.1%) patients who are HER2 positive, were not included in the survival analysis, because we could use trastuzumab only in 6 of these 64 patients. In the analysis of survival, the 5-year DFS, 10-year DFS, 5-year DSS, and 10-year DSS rates were 86.3%, 80.3%, 93.8%, and 84.1%, respectively. The evaluation according to the anatomical and pathologic prognostic stage groups revealed a similarity among stage IA, IIA, IIB, and IIIA groups, with relatively high numbers of patients in terms of 5-year and 10-year DFS and DSS rates. According to the pathological prognostic stage, there was obviously more downstaging. There was only 1 patient at stage IB in the anatomic stage group, while 68 (23.5%) patients were found to be classified as stage IB in the pathologic prognostic stage group due to stage change. The 5-year DFS, 10-year DFS, 5-year DSS, and 10-year DSS rates were 93.8%, 88.8%, 98.4%, and 91.5%, respectively. This result highlights the presence of patients with very good prognosis, even in the higher stages (Table 4 ). In addition, after the pathological prognostic stage group changes were made in each anatomic stage group, the groups were compared with the chi-square test. A statistically significant difference was found only in the pathological prognostic stage groups of the anatomic stage group IIB and IIIA. A total of 58 patients were in the anatomical stage group IIB. When they were staged according to the pathological prognostic stage group,15 patients were unchanged (pathologic prognostic stage IIB), 4 patients were +1 upstaged (pathologic prognostic stage IIIA), 19 patients were -1 downstaged (pathologic prognostic stage IIA), and 20 patients were -2 downstaged (pathologic prognostic stage IB). The 10-year DFS was 70% in patients without stage change, whereas the 10-year DFS was 94.7% in patients with -2 downstaged patients (p=0.003). A total of 44 patients were in anatomical stage group IIIA. After staging these patients according to the pathological prognostic staging, in 11 patients there was no stage change (pathologic prognostic stage IIIA), in 4 patients there was +2 upstaging (pathologic prognostic stage IIIC), in 16 patients there was -1 downstaging (pathologic prognostic stage IIB), and in 13 patients there was -3 downstaging (pathologic prognostic stage IB). The 10-year DFS rate was 27.3% in patients without stage change and 91.7% in patients with -3 downstaging (p=0.003); the 10-year DSS was 30.7% in patients without stage change and 91.7% in patients with -3 downstaging (p=0.010) ( 
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Discussion
Breast cancer treatment is based on both anatomical and biologic characteristics [6] . Greater understanding of cancer biology has been accompanied by identification and validation of biological markers of the treatment benefits and prognosis [7] . The aim of cancer staging is to identify the prevalence of the disease and to help to develop the treatment plan, as well as to provide information about the prognosis [8] . At the end of 2016, the AJCC Cancer Staging Manual 8 th Edition was published [1, 9] . In this staging system, the prognostic stage was defined by using T, N, M, ER, PR, HER2 status, and grade information. After Oncotype DX multi-gene analysis was applied in the group of those with T1-T2, N0, M0, ER-positive, and HER2-negative, if the recurrence score was <11, it was classified as IA. After the publication of the AJCC 8 th Edition staging manual, this prognostic staging was validated in additional cohorts [8, [10] [11] [12] [13] [14] [15] . In some of these studies, anatomical and prognostic stage survival analysis of the AJCC 8 th Edition was performed in breast cancer subgroups, and in some studies the general group of patients with non-metastatic invasive breast cancer was analyzed [8, [10] [11] [12] [13] [14] [15] . Hu et al. evaluated the stage changes in the AJCC 8 th Edition according to the anatomical and prognostic stage system [16] . Ye et al. aimed to make a prognostic evaluation in luminal-A breast cancer by using AJCC 8 th Edition [11] . They found 412 luminal-A patients DFS and overall survival (OS) rates were 98.3% and 99.3%, respectively. There was a significant difference in the 5-year DFS rate of different anatomic stages. No difference was found in OS but there was a significant difference between different prognostic stages in 5-year DFS and OS rates. They reported stage changes in 41.6% of the patients through the prognostic staging system. Zhou et al. analyzed the prognostic value of the anatomical stage and prognostic stage groups in 170 HER2-positive breast cancer patients [15] . They showed that both anatomic stage and prognostic stage have prognostic value in HER2-positive breast cancer. Both anatomic stage and prognostic stage were significant prognostic markers for DFS and OS. In multivariate analysis, both groups were independent predictors of OS. Wang et al., in their prognostic evaluation study of the AJCC 8 th Edition, reported that the prognostic stage provided more correct information in locally advanced 
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This work is licensed under Creative Common AttributionNonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) breast cancer compared with the anatomic TNM stage [12] . Abdel-Rahman reported in 209 304 patients with non-metastatic breast cancer that AJCC 8 th Edition prognostic stage system showed an improvement in determination of prognosis when compared with the anatomic staging system [14] . Finally, the prognostic stage gave better prognostic information than the anatomical stage in the single-institution cohort and a large population database study carried out with 3327 patients with Edition published at the end of 2016 was used [1] . However, in December 2017, the AJCC 8 th Edition was updated with the new data. The new staging system offers a pathologic prognostic staging for patients who underwent surgery as the initial treatment.
While staging our study population according to the updated version of the AJCC 8 th Edition updated staging system, we evaluated the distribution of stages in the new staging system according to anatomic stage and DFS-DSS rates. Our work has some limitations. It is primarily a retrospective study and the number of patients is relatively limited. However, it appears to be the first study comparing the anatomical stage and the pathological prognostic stage groups. We showed that the reevaluation of anatomical stage as the pathologic prognostic stage was mostly presented as downstaging. After pathologic prognostic staging in anatomical stage IIIA group, 4 different groups were established (unchanged, +1 upstaged, -1 downstaged, and -3 downstaged). The comparison among these groups showed statistically significant differences in survival in 10-year DFS and DSS rates. After pathologic prognostic staging in the anatomical stage IIB group, 4 different groups were established (unchanged, +1 upstaged, -1 downstaged, and -2 downstaged). There was a significant difference in 10-year DFS among groups, whereas no significant difference was found among groups in terms of 10-year DSS (which was nearly statistically significant). Studies with larger series are needed to 
